Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Sunitinib, an antiangiogenic drug, has not been previously studied as a single agent in patients with untreated breast cancer.
• Locally advanced or operable breast cancer requires novel therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of sunitinib, alone and in combination with docetaxel, in patients with untreated breast cancer.
• To investigate the mechanisms underlying response and resistance to sunitinib treatment.

Main Methods:

• A window study design was employed, with an initial sunitinib monotherapy phase followed by sunitinib plus docetaxel.
• Response, resistance, and toxicity were assessed using clinical parameters, advanced imaging (MRI, PET), and comprehensive pathology including gene expression profiling.
• Tumor gene expression profiling was used to compare responders and non-responders.

Main Results:

• Primary resistance to sunitinib was observed in a significant proportion of patients during the initial monotherapy phase.
• Unacceptable toxicity led to study withdrawal for some patients, and no complete clinical responses were achieved.
• Gene expression analysis revealed upregulation of VEGF and angiogenic pathways in non-responders, alongside a transcriptional response to hypoxia characterized by HIF1α target gene overexpression.

Conclusions:

• Single-agent sunitinib demonstrates primary resistance in untreated localized breast cancer, suggesting limitations in its use.
• Hypoxia-responsive gene upregulation appears to be a key mechanism mediating resistance to sunitinib.
• Further investigation into combination therapies and resistance mechanisms is warranted for effective breast cancer treatment.